New drug cocktail aims to shrink ovarian tumors before surgery
NCT ID NCT07663513
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This phase 2 trial tests a new immunotherapy combination (iparomlimab and tovorilimab) plus standard chemotherapy and bevacizumab before surgery in 36 women with advanced ovarian cancer. The main goal is to see how many patients achieve complete tumor removal (R0 resection). The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university cancer hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tovorilimab (QL1706) plus bevacizumab, paclitaxel, and carboplatin
What this could lead to
If successful, this could offer a more effective pre-surgery treatment for advanced ovarian cancer, potentially improving the chance of complete tumor removal and long-term control.
What could go wrong
This is a small, early-phase study with only 36 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.